These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 24470552

  • 1. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
    Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.
    Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
    [Abstract] [Full Text] [Related]

  • 2. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.
    Clin Cancer Res; 2006 Nov 15; 12(22):6791-9. PubMed ID: 17121900
    [Abstract] [Full Text] [Related]

  • 3. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
    Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP.
    Mol Ther; 2007 Feb 15; 15(2):279-86. PubMed ID: 17235305
    [Abstract] [Full Text] [Related]

  • 4. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
    Mahller YY, Rangwala F, Ratner N, Cripe TP.
    Pediatr Blood Cancer; 2006 Jun 15; 46(7):745-54. PubMed ID: 16124003
    [Abstract] [Full Text] [Related]

  • 5. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
    Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.
    Neoplasia; 2013 Jun 15; 15(6):591-9. PubMed ID: 23730207
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, Pikarsky E, Rabkin SD, Panet A, Zamir G.
    Gene Ther; 2009 Jul 15; 16(7):905-15. PubMed ID: 19440231
    [Abstract] [Full Text] [Related]

  • 15. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J, Hu P, Zeng M, Rabkin SD, Liu R.
    Int J Oncol; 2012 Mar 15; 40(3):757-63. PubMed ID: 22108767
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL.
    Clin Cancer Res; 2011 Dec 01; 17(23):7383-93. PubMed ID: 21976549
    [Abstract] [Full Text] [Related]

  • 20. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED, Meza-Perez S, Bevis KS, Randall TD, Gillespie GY, Langford C, Alvarez RD.
    J Ovarian Res; 2016 Oct 27; 9(1):70. PubMed ID: 27784340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.